文献速递前列腺癌男科与性医学

有前列腺癌病史的男性在接受睾酮治疗时的PSA检测:一项大型多机构研究网络的匹配分析

PSA Testing in Men Receiving Testosterone Therapy With History of Prostate Cancer: A Matched Analysis of a Large Multi-Institutional Research Network.
PubMed 文献 · Urology · 2022-02-25

结果显示,无前列腺癌且未接受睾酮治疗者PSA检测率为14.2%,无前列腺癌但接受睾酮治疗者为33.6%,而接受睾酮治疗且有未经治疗或已经治疗前列腺癌病史者PSA检测率分别仅为53.2%和61.0%(所有比较P<.0001)。作者结论认为,与现行指南相反,大量接受睾酮治疗且有前列腺癌病史的男性未进行PSA检测,需进一步研究明确原因。

要点

  • 接受睾酮治疗且有前列腺癌病史的男性中,仅53.2%(未经治疗)和61.0%(已经治疗)进行了PSA检测。
  • 无前列腺癌且未接受睾酮治疗者PSA检测率为14.2%,无前列腺癌但接受睾酮治疗者为33.6%。
  • 作者认为该结果与现行指南相反,并指出需进一步研究PSA检测率低的原因。

核心结论

  • 与现行指南相反,大量接受睾酮治疗且有前列腺癌病史的男性未进行PSA检测。
  • 作者指出需进一步研究以更好地明确即使在这一高风险队列中PSA检测率仍较低的原因。

研究设计与样本

  • 研究纳入4525259名55-69岁、有前列腺癌诊断史和/或接受任何途径或剂型睾酮处方的男性,分为4个队列。
  • 各队列进一步分层,以评估既往接受过治疗(CPT 55,840、55,866、77,778、77,385)或未经治疗的前列腺癌男性的PSA检测情况。
  • 所有队列的PSA检测率均通过卡方检验与「无前列腺癌且无睾酮治疗」队列进行比较。

主要发现

  • 无前列腺癌且未接受睾酮治疗的男性在初次门诊就诊后PSA检测率为14.2%(P < .0001)。
  • 无前列腺癌但接受睾酮治疗的男性PSA检测率为33.6%(P < .0001)。
  • 接受睾酮治疗且有未经治疗前列腺癌病史的男性PSA检测率为53.2%(P < .0001)。
  • 接受睾酮治疗且有已经治疗前列腺癌病史的男性PSA检测率为61.0%(P < .0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需进一步研究以更好地明确即使在这一高风险队列中PSA检测率仍较低的原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the frequency of prostate-specific antigen (PSA) testing in men receiving testosterone replacement therapy (TT) and with a history of prostate cancer (PCa). METHODS: We queried the TriNetX network database, a global health research network consisting of 65 million men in 44 large healthcare organizations, to investigate rates of PSA testing in 4 cohorts of men aged 55-69 with a history of PCa diagnosis and/or a prescription for any route or formulation of testosterone. We further stratified each cohort to evaluate PSA testing in men with previously treated (CPT 55,840, 55,866, 77,778, 77,385) or untreated PCa. All cohorts' PSA testing rates were compared against the "no PCa or TT" cohort by Chi-square test. RESULTS: A total of 4,525,259 men, aged 55-69, were included in our study. Following stratification into cohorts based on PCa or TT history, we found that 14.2% (P < .0001) of men without PCa or TT underwent PSA testing following an initial ambulatory visit. Among men without PCa who received TT, 33.6% (P < .0001) underwent testing. Unfortunately, only 53.2% (P < .0001) and 61.0% (P < .0001) of men receiving TT with previously untreated and treated PCa, respectively, had PSA testing. CONCLUSION: In contrast to current guidelines, a large proportion of men receiving TT and with a history of PCa did not undergo PSA testing. Further studies are necessary to better characterize reasons why PSA testing rates are low even in this high-risk cohort.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Mason MM, Nackeeran S, Lokeshwar SD, et al. PSA Testing in Men Receiving Testosterone Therapy With History of Prostate Cancer: A Matched Analysis of a Large Multi-Institutional Research Network. Urology. 2022. PMID: 35227710. doi:10.1016/j.urology.2022.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。